Comparative efficacy and tolerability of paroxetine and amitriptiline in long-term therapy preventing depressive recurrences
Mosolov, S.N.; Kostiukova, E.G.; Gorodnichev, A.V.; Timofeev, I.V.
Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 105(10): 22-29
2005
ISSN/ISBN: 1997-7298 PMID: 16281375 Document Number: 591556
An open comparative randomized study of paroxetine (selective inhibitor of serotonin re-uptake) and tricyclic antidepressant amitriptiline has been conducted. These drugs were used for the treatment of 43 patients with recurrent depression (RD) with frequent relapses (ICD-10 F33.0-F33.2) during 12 months. There were 2 groups matched for demographic and clinical data, one included 21 patients treated by paroxetine and the other 22 patients switched to amitriptiline. Basing on clinical records and scores on a number of scales, i.e. HAM-D, CGI, quality of life, high efficacy of the drugs was confirmed, being estimated as 90,5% responders in the paroxetine group and 69,2% in the amitriptiline one, with the marked advantage of the former medication. The better tolerability, possibility of single intake and absence of severe side-effects argue for preferable use of paroxetine during long-term therapy in RD patients with frequent relapses.